Drug therapy: Dopamine agonists

Principles of Treatment in Parkinson's Disease

Volumn , Issue , 2005, Pages 25-47

  Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947324622     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7506-5428-9.50006-8     Document Type: Chapter

References (90)

1. Calne DB, Teychenne PF, Claveria LE, et al. Bromocriptine in parkinsonism. Br Med J 1974, 4:442-444.
2. Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK Treatment of parkinsonism with bromocriptine. Lancet 1974, 2:1355-1356.
3. Schwartz J-C, Giros B, Martres M-P, Sokoloff P The dopamine receptor family: molecular biology and pharmacology. Sem Neurosci 1992, 4:99-108.
4. Grandy DK, Marchionni MA, Makan H, et al. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 1989, 84:9762-9766.
5. Sunahara RK, Niznik HB, Weiner DM, et al. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature 1990, 347:80-83.
6. Van Tol HHM, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991, 350:610-614.
7. Tiberi M, Jarvie KR, Silvia C, et al. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Proc Natl Acad Sci USA 1991, 88:7491-7495.
8. Le Coniat M, Sokoloff P, Hillion J, et al. Chromosomal localization of the human D3 dopamine receptor gene. Hum Genet 1991, 87:618-620.
9. Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146-151.
10. Haverstick D, Rubestein A, Bannon M Striatal tachykinin gene expression regulated by interaction of D-1 and D-2 dopamine receptors. J Pharmacol Exp Ther 1989, 248:858-862.
11. Bedard PJ, Gomez-Mancilla B, Blanchette P, et al. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. Adv Neurol 1993, 60:113-118.
12. Olanow CW, Jenner P, Brooks D Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998, 44(1):S167-174.
13. Yamamoto M Do dopamine agonists provide neuroprotection?. Neurology 1998, 51(2):S10-12.
14. Olanow CW, Schapira AHV, Agid Y Neuroprotection for Parkinson's disease: prospects and promises. Ann Neurol 2003, 53(3):1-2.
15. Olanow CW Single blind double observer-controlled study of carbidopa/levodopa vs bromocriptine in untreated Parkinson patients. Arch Neurol 1988, 45:206.
16. Staal-Schreinemachers AL, Wesseling H, Kamphuis DJ, Burg WVD, Lakke JPWF Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology 1986, 36:291-293.
17. Lees AJ, Stern GM Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981, 44:1020-1023.
18. Parkinson's Disease Research Group in the United Kingdom Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br Med J 1993, 307:469-472.
19. Montastruc JL, Rascol O, Senard JM, Rascol A A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry 1994, 57:1034-1038.
20. Hely MA, Morris JGL, Reid WGJ The Sydney multicentre study of Parkinson's disease: a randomized, prospective five year study comparing low dose bromocriptine with low dose levodopacarbidopa. J Neurol Neurosurg Psychiatry 1994, 57:903-910.
21. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y Ten-year follow-up of three different initial treatments in de-novo PD: a randomised trial. Neurology 2001, 57:1687-1694.
22. Mizuno Y, Kondo T, Narabayashi H Pergolide in the treatment of Parkinson's disease. Neurology 1995, 45(31):S13-21.
23. Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. The 053 Study Group. Mov Disord 1998, 13:46-51.
24. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 1999, 53:364-370.
25. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995, 38:771-777.
26. Hoehn MMM, Elton RL Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985, 35:199-206.
27. Toyokura Y, Mizuno Y, Kase M, et al. Effects of bromocriptine on parkinsonism: a nationwide collaborative double-blind study. Acta Neurol Scand 1985, 72:157-170.
28. Guttman M, International Pramipexole-Bromocriptine Study Group Double-blind randomized, placebo controlled study to compare safety, tolerance and efficacy of pramipexole and bromocriptine in advanced Parkinson's disease. Neurology 1997, 49:1060-1065.
29. Inzelberg R, Nisipeaunu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996, 47:785-788.
30. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, cross-over, controlled study. Mov Disord 1994, 9:431-436.
31. Boas J, Worm-Petersen J, Dupont E, Mikkelsen B, Wermuth L The levodopa dose-sparing of pergolide compared with that of bromocriptine in an open-label, cross-over study. Eur J Neurol 1996, 3:44-49.
32. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O Sleep attacks and Parkinson's disease treatment. Lancet 2000, 355:1333-1334.
33. Ben-Noun L Drug-induced respiratory disorders: incidence, prevention and management. Drug Saf 2000, 23:143-164.
34. Quinn N, Illas A, Lhermitte F, Agid Y Bromocriptine and domperidone in the treatment of Parkinson's disease. Neurology 1981, 31:662-667.
35. Bergamasco B, Frattola L, Muratorio A, et al. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurol Scand 2000, 101:372-380.
36. Martignoni E, Pacchetti C, Sibilla L, et al. Dihydroergocryptine in the treatment of Parkinson's disease: a six month's double-blind clinical trial. Clin Neuropharmacol 1991, 14:78-83.
37. Oechsner M, Groenke L, Mueller D Pleural fibrosis associated with dihydroergocryptine treatment. Acta Neurol Scand 2000, 101:283-285.
38. Fariello RG Pharmacodynamic and pharmacokinetic features of cabergoline: rationale for use in Parkinson's disease. Drugs 1998, 55(1):10-16.
39. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997, 48:363-368.
40. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Drugs 1998, 55(1):23-30. and the PKDS009 Study Group.
41. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996, 46:1062-1065.
42. Ebersbach G, Norden J, Tracik F Sleep attacks in Parkinson's disease: polysomnographic recordings. Mov Disord 2000, 15(3):89.
43. Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999, 74:371-375.
44. Rinne UK Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989, 39:336-339.
45. Allain H, Destée A, Petit H, et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de-novo Parkinson's disease. The French Lisuride Study Group. Eur Neurol 2000, 44:22-30.
46. LeWitt PA, Gopinathan G, Ward CD, et al. Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study. Neurology 1982, 32:69-72.
47. Laihinen A, Rinne UK, Suchy I Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease. Acta Neurol Scand 1992, 86:593-595.
48. Battistin L, Bardin PG, Ferro-Milone F, et al. Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study. Acta Neurol Scand 1999, 99:36-42.
49. Obeso JA, Luquin MR, Martinez-Lage JM Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. Lancet 1986, 1(8479):467-470.
50. Vaamonde J, Luquin MR, Obeso JA Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. Brain 1991, 114:601-617.
51. Chase TN, Engber TM, Mouradian MM Striatal dopaminoceptive system changes and motor response complications in levodopa-treated patients with advanced Parkinson's disease. Adv Neurol 1993, 60:181-185.
52. Stocchi F, Ruggieri S, Vacca L, Olanow CW Prospective randomised trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002, 125:2058-2066.
53. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD. A randomized controlled study. Neurology 1999, 53:573-579. and the Pergolide Monotherapy Study Group.
54. Oertel WH Pergolide versus levodopa (PELMOPET). Mov Dis 2000, 15(3):4.
55. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994, 9:40-47.
56. Schapira AH Sleep attack (sleep episodes) with pergolide. Lancet 2000, 355:1332-1333.
57. Gancher ST, Woodward WR, Boucher B, Nutt JG Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989, 26:232-238.
58. Durif F, Deffond D, Tournilhac M, et al. Efficacy of sublingual apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990, 53:1105.
59. Kapoor R, Turjanski N, Frankel J, et al. Intranasal apomorphine: a new treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990, 53:1015.
60. van Laar T, Jansen EN, Neef C, Danhof M, Roos RA Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Dis 1995, 10:433-439.
61. Poewe W, Wenning GK Apomorphine: an underutilized therapy for Parkinson's disease [review]. Mov Dis 2000, 15:789-794.
62. Dewey RB, Hutton JT, LeWitt PA, Factor SA A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001, 58:1385-1392.
63. Frankel JP, Lees AJ, Kempster PA, Stern GM Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990, 53:96-101.
64. Colzi A, Turner K, Lees AJ Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998, 64:573-576.
65. Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease: long-term follow-up in 18 patients. Adv Neurol 1993, 60:656-659.
66. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995, 18:338-347.
67. Parkinson Study Group Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997, 278:125-130.
68. Shannon KM, Bennett JP, Friedman JH, for the Pramipexole Study Group Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997, 49:724-728.
69. Parkinson Study Group Pramipexole vs levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA 2000, 284:1931-1938.
70. Parkinson Study Group Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287:1653-1661.
71. Ahlskog JE Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003, 60:381-389.
72. Lieberman A, Ranhosky A, Korts D Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997, 49:162-168.
73. Wermuth L, the Danish Pramipexole Study Group A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol 1998, 5:235-242.
74. Pinter MM, Pogarell O, Oertel WH Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double-blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999, 66:436-441.
75. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double-blind, placebo-controlled multicentre study. J Neurol Neurosurg Psychiatry 2002, 72:713-720.
76. Frucht S, Rogers JD, Greene PE, Gordon MS, Fahn S Falling asleep at the wheel: motor vehible mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908-1910.
77. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997, 49:393-399. for the Ropinirole Study Group.
78. Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998, 21:101-107.
79. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342:1484-1491. for the 056 Study Group.
80. Whone AL, Watts RL, Stoessl AJ, et al. REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa. Ann Neurol 2003, 54:93-101.
81. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 1998, 13:39-45. on behalf of the 056 Study Group.
82. Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996, 19:234-245.
83. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998, 51:1057-1062. and the Ropinirole Study Group.
84. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002, 359:1589-1598.
85. Facca A, Sanchez-Ramos J High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 1996, 11:327-329.
86. Olanow CW, Alberts MJ Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease. Clin Neuropharmacol 1987, 10:178-185.
87. Jankovic J, Orman J Parallel double-blind study of pergolide in Parkinson's disease. Adv Neurol 1987, 45:551-554.
88. Diamond SG, Markham CH, Treciokas LJ Double-blind trial of pergolide for Parkinson's disease. Neurology 1985, 35:291-295.
89. Geminiani G, Fetoni V, Genitrini S, et al. Cabergoline in Parkinson's disease complicated by motor fluctuations. Mov Disord 1996, 11:495-500.
90. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996, 243:68-72.